Internal documents show contractor readiness concerns, decision delays, and high non-affirmation rates, while providers ...

Abemaciclib and ribociclib now show adjuvant survival benefit; palbociclib didn't. Laura Spring, MD, on picking the right agent per patient.

Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy.

Cancer diagnoses among people exposed to the World Trade Center disaster continue to be reported 25 years after 9/11, ...

JAK inhibitors are linked to reduced disease activity and improved patient-reported outcomes in patients with rheumatoid arthritis, regardless of diabetes, cardiometabolic burden, or age.

Survivors of bacterial meningitis have modestly higher mortality than their peers over nearly six decades, and their siblings ...

For patients with small-cell lung cancer, skipping preventive cranial radiotherapy in favor of MRI monitoring may improve outcomes.

The modified Medical Research Council questionnaire (mMRC) and COPD Assessment Test (CAT) are objective measures of symptoms in patients with COPD, said lead author Andrew J. Gangemi, MD, associate ...

An AI algorithm accurately evaluates pathologic response after neoadjuvant chemoimmunotherapy in patients with NSCLC, showing moderate concordance with expert pathologist consensus across cohorts.

The agency expresses concern that a rise in use of postexposure prophylaxis could indicate a lack of understanding of when to administer the therapy.

An integrated inherited risk measure may stratify the risk for early-onset colorectal cancer in adults younger than 50 years, ...

If approved by the FDA, tavapadon would be the first new dopamine agonist for Parkinson's disease in decades. What does the ...